Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The EMIF-AD Multimodal Biomarker Discovery study: Design, methods and cohort characteristics

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hospital readmissions following infections in dementia: a nationwide and registry-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Associations between oxidative stress and perceived stress in patients with bipolar disorder and healthy control individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Barriers in access to dementia care in minority ethnic groups in Denmark: a qualitative study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Guidelines should be guidelines: Time to leave the terms "consensus" and "position" for other purposes

    Research output: Contribution to journalEditorialResearchpeer-review

View graph of relations

Background: In clinical practice, it is often difficult to predict which patients with cognitive complaints or impairment will progress or remain stable. We assessed the impact of using a clinical decision support system, the PredictND tool, to predict progression in patients with subjective cognitive decline (SCD) and mild cognitive impairment (MCI) in memory clinics. Methods: In this prospective multicenter study, we included 429 patients with SCD (n = 230) and MCI (n = 199) (female 54%, age 67 ± 9, MMSE 28 ± 2) and followed them for at least 12 months. Based on all available patient baseline data (demographics, cognitive tests, cerebrospinal fluid biomarkers, and MRI), the PredictND tool provides a comprehensive overview of the data and a classification defining the likelihood of progression. At baseline, a clinician defined an expected follow-up diagnosis and estimated the level of confidence in their prediction using a visual analogue scale (VAS, 0-100%), first without and subsequently with the PredictND tool. As outcome measure, we defined clinical progression as progression from SCD to MCI or dementia, and from MCI to dementia. Correspondence between the expected and the actual clinical progression at follow-up defined the prognostic accuracy. Results: After a mean follow-up time of 1.7 ± 0.4 years, 21 (9%) SCD and 63 (32%) MCI had progressed. When using the PredictND tool, the overall prognostic accuracy was unaffected (0.4%, 95%CI - 3.0%; + 3.9%; p = 0.79). However, restricting the analysis to patients with more certain classifications (n = 203), we found an increase of 3% in the accuracy (95%CI - 0.6%; + 6.5%; p = 0.11). Furthermore, for this subgroup, the tool alone showed a statistically significant increase in the prognostic accuracy compared to the evaluation without tool (6.4%, 95%CI 2.1%; 10.7%; p = 0.004). Specifically, the negative predictive value was high. Moreover, confidence in the prediction increased significantly (Δ VAS = 4%, p <.0001). Conclusions: Adding the PredictND tool to the clinical evaluation increased clinicians' confidence. Furthermore, the results indicate that the tool has the potential to improve prediction of progression for patients with more certain classifications.

Original languageEnglish
Article number25
JournalAlzheimer's research & therapy
Issue number1
Pages (from-to)25
Publication statusPublished - Mar 2019

    Research areas

  • Alzheimer's disease, CDSS, Computer-assisted, Conversion, Dementia, Mild cognitive impairment, Progression, Subjective cognitive decline

ID: 58019619